Free Trial
Earnings Season Is Here. MarketBeat All Access for Just $149
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Get the Deal
Claim MarketBeat All Access Sale Promotion
NYSE:TMO

Thermo Fisher Scientific (TMO) Stock Price, News & Analysis

Thermo Fisher Scientific logo
$694.49 +9.60 (+1.40%)
Closing price 10/27/2026 03:59 PM Eastern
Extended Trading
$691.96 -2.53 (-0.36%)
As of 04:28 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Thermo Fisher Scientific Stock (NYSE:TMO)

Advanced

Key Stats

Today's Range
$676.00
▼
$700.99
50-Day Range
$590.00
▼
$695.75
52-Week Range
$435.27
▼
$705.78
Volume
1.83 million shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
36.63
Dividend Yield
N/A
Price Target
$681.00
Consensus Rating
Moderate Buy

Company Overview

Thermo Fisher Scientific Inc. is a global supplier of laboratory products, analytical instruments, reagents, consumables, software and services used in scientific research, healthcare, pharmaceuticals, biotechnology and industrial applications. The company serves customers ranging from academic institutions and government agencies to hospitals, clinical laboratories and pharmaceutical manufacturers.

Its offerings include instruments and systems for genetic analysis, mass spectrometry, chromatography, electron microscopy and materials science, as well as molecular biology reagents, cell culture products, laboratory plastics and research chemicals. Through its laboratory services and contract development and manufacturing operations, Thermo Fisher also supports pharmaceutical and biotechnology companies with drug development, clinical research and manufacturing services.

The company operates internationally through brands including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. Its products and services are distributed and provided across North America, Europe, Asia-Pacific and other global markets.

Thermo Fisher Scientific was formed in 2006 through the merger of Thermo Electron and Fisher Scientific. Marc N. Casper serves as the company’s president and chief executive officer.

AI Generated. May Contain Errors.

Thermo Fisher Scientific Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
84th Percentile Overall Score

TMO MarketRank™: 
4.183384946815 of 5 stars

Thermo Fisher Scientific scored higher than 84% of companies evaluated by MarketBeat, and ranked 60th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Thermo Fisher Scientific has received a consensus rating of Moderate Buy. The company's average rating score is 2.84, and is based on 2 strong buy ratings, 18 buy ratings, 4 hold ratings, and 1 sell rating.

  • Upside/Downside

    The consensus price target for Thermo Fisher Scientific is close to its current price, suggesting limited near-term upside or downside.

  • Amount of Analyst Coverage

    Thermo Fisher Scientific has been the subject of 18 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Thermo Fisher Scientific's stock forecast and price target.
  • Earnings Growth

    Earnings for Thermo Fisher Scientific are expected to grow by 10.03% in the coming year, from $25.23 to $27.76 per share.

  • Percentage of Shares Shorted

    1.33% of the float of Thermo Fisher Scientific has been sold short.
  • Short Interest Ratio / Days to Cover

    Thermo Fisher Scientific has a short interest ratio ("days to cover") of 2.15, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Thermo Fisher Scientific has recently decreased by 9.63%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Thermo Fisher Scientific does not currently pay a dividend.

  • Dividend Growth

    Thermo Fisher Scientific has been increasing its dividend for 8 years.

  • Dividend Sustainability

    Based on earnings estimates, Thermo Fisher Scientific will have a dividend payout ratio of 6.77% next year. This indicates that Thermo Fisher Scientific will be able to sustain or increase its dividend.

  • News Sentiment

    Thermo Fisher Scientific has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 65 news articles for Thermo Fisher Scientific this week, compared to 9 articles on an average week.
  • Search Interest

    40 people have searched for TMO on MarketBeat in the last 30 days. This is an increase of 82% compared to the previous 30 days.
  • MarketBeat Follows

    15 people have added Thermo Fisher Scientific to their MarketBeat watchlist in the last 30 days. This is an increase of 650% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Thermo Fisher Scientific insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $43,896,820.00 in company stock.

  • Percentage Held by Insiders

    0.33% of the stock of Thermo Fisher Scientific is held by insiders.

  • Percentage Held by Institutions

    89.23% of the stock of Thermo Fisher Scientific is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Thermo Fisher Scientific's insider trading history.
Receive TMO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Thermo Fisher Scientific and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

TMO Stock News Headlines

3 healthcare stocks we keep off our radar
DO YOU LIVE HERE? ⬇️
Data centers now number about 1,300 across the US, with another 2,500 planned. Each can draw as much power as 100,000 homes, and one Virginia homeowner saw his bill jump from $100 to $281 in a single month. Elon Musk has filed a plan with the FCC to move data centers out of cities entirely, a move backed by President Trump. One lesser-known, publicly traded company trading under $100 a share may sit at the center of that shift.tc pixel
Thermo Fisher Scientific (NYSE:TMO) Cut to Hold at DZ Bank
AI Is Speeding Up Drug Discovery, but FDA Trial Phases Still Decide Which Biotech Stocks Win
Quantum BioPharma’s Phase 2 Shows Where Biotech Value Actually Gets Built (TMO)
Biotech stocks trade on FDA trial phases. Phase 2 data often builds value, cash runway limits dilution, and Quantum BioPharma just began a phase 2 MS trial.
See More Headlines

TMO Stock Analysis - Frequently Asked Questions

Thermo Fisher Scientific's stock was trading at $579.42 at the start of the year. Since then, TMO stock has increased by 19.9% and is now trading at $694.4940.

Thermo Fisher Scientific Inc. (NYSE:TMO) announced its earnings results on Wednesday, October, 21st. The medical research company reported $6.68 EPS for the quarter, topping the consensus estimate of $6.40 by $0.28. The business's quarterly revenue was up 9.1% on a year-over-year basis.
Read the conference call transcript
.

Thermo Fisher Scientific's board initiated a share buyback plan on Thursday, November 6th 2025, which authorizes the company to repurchase $5 billion in outstanding shares, according to EventVestor. This means that the company could reacquire up to 2.4% of its stock through open market purchases. Stock buyback plans are typically an indication that the company's leadership believes its stock is undervalued.

Thermo Fisher Scientific subsidiaries include Henogen, Phinotex, Qiagen, Brammer Bio, HighChem, Gatan Inc, IntegenX, and others.

Thermo Fisher Scientific's top institutional shareholders include Canoe Financial LP (0.08%), James Hambro & Partners LLP (0.06%), Asset Management One Co. Ltd. (0.06%) and Douglas Lane & Associates LLC (0.06%). Insiders that own company stock include Marc N Casper, Michel Lagarde, Stephen Williamson, Gianluca Pettiti, Michael D Shafer, Lisa P Britt, Frederick M Lowery, Michael A Boxer, Joseph R Holmes and Debora L Spar.
View institutional ownership trends
.

Shares of TMO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Thermo Fisher Scientific investors own include NVIDIA (NVDA), Visa (V), Salesforce (CRM), Advanced Micro Devices (AMD), Tesla (TSLA), Mastercard (MA) and JPMorgan Chase & Co. (JPM).

Company Calendar

Record date for 10/15 Dividend
9/15/2026
Ex-Dividend for 10/15 Dividend
9/15/2026
Dividend Payable
10/15/2026
Last Earnings
10/21/2026
Today
10/27/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Life Sciences Tools & Services
Sub-Industry
Life Sciences Tools & Services
Current Symbol
NYSE:TMO
CIK
97745
Employees
125,000
Year Founded
1956

Price Target and Rating

High Price Target
$810.00
Low Price Target
$520.00
Potential Upside/Downside
-1.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.84
Research Coverage
25 Analysts

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
36.63
Forward P/E Ratio
27.53
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
368,527,000
Market Cap
N/A
Optionable
Optionable
Beta
N/A

Social Links

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NYSE:TMO) was last updated on 10/27/2026 by MarketBeat.com Staff.
From Our Partners